(NASDAQ: KYNB) Kyntra Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.8%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.78%.
Kyntra Bio's earnings in 2026 is $183,192,000.On average, 6 Wall Street analysts forecast KYNB's earnings for 2026 to be -$39,863,626, with the lowest KYNB earnings forecast at -$53,212,778, and the highest KYNB earnings forecast at -$28,230,493. On average, 6 Wall Street analysts forecast KYNB's earnings for 2027 to be -$46,690,854, with the lowest KYNB earnings forecast at -$65,275,928, and the highest KYNB earnings forecast at -$31,844,336.
In 2028, KYNB is forecast to generate -$48,807,736 in earnings, with the lowest earnings forecast at -$77,537,485 and the highest earnings forecast at -$28,698,166.